Village Farms International, Inc. (VFF) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows strong financial performance with a 27% increase in net sales and a 118% rise in EBITDA. The share repurchase program and increased gross margins are positive indicators. Although cash flow was negative, it is expected to improve. The Q&A section highlighted management's prudent approach to M&A and confidence in market strategy, despite some reluctance to disclose margin details. Overall, the company's performance and strategic decisions suggest a positive outlook for the stock price.
Key Financial Performance
Total Net Sales $50.2 million, a 27% increase year-over-year. This growth was driven by strong performance in international business and leadership in Canada.
Consolidated Adjusted EBITDA $9.9 million, a 118% increase year-over-year. This growth significantly outpaced sales and reflects sustainable profitability of the global cannabis enterprise.
International Export Sales $15 million, a 171% increase year-over-year and 60% sequentially. Growth was driven by strong performance in the German market and other international markets.
Cannabis Gross Margin 43%, up from 39% year-over-year. This improvement reflects higher international export sales, contributions from Netherlands operations, and a shift toward higher-margin products in Canada.
Net Income from Continuing Operations $2.7 million, compared to a net loss of $2.1 million year-over-year. This improvement demonstrates profitability.
Canadian Corporate Income Taxes CAD 16.4 million (USD 12.1 million) paid in Q1 2026. This reflects the utilization of carryover tax losses and strong operating capabilities.
Cash Flow from Operations Negative $16.8 million, impacted by Canadian corporate income tax payments and investments in working capital. Expected to return to positive cash flow in Q2 2026.
Branded Sales in Canada 5% increase year-over-year. Growth was driven by a shift towards higher-margin products and strong consumer and brand loyalty.
Adjusted EBITDA Margin 20%, up from 11.4% year-over-year. This reflects improved operational efficiency and profitability.
Excise Taxes on Retail Branded Sales in Canada $15.9 million, nearly 40% of gross retail branded sales. This reflects the tax burden on the Canadian cannabis market.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EU GMP-compliant cannabis production: Facility upgrades in British Columbia have significantly expanded production capacity, making it the world's largest EU GMP-certified cannabis facility.
Delta 2 greenhouse expansion: First harvest expected in May 2026, with a 33% increase in British Columbia cannabis production by mid-2027.
New product categories: Exploring opportunities to export non-flower cannabis products to international partners.
International medical cannabis exports: Sales increased 171% year-over-year and 60% sequentially, with Germany being a key market.
Canadian market share: Maintained top 5 overall share in Canada's adult-use market and #1 in dried flower.
Netherlands recreational cannabis: Phase 2 facility in Groningen completed, awaiting regulatory approval to commence operations.
Cost efficiency: Continued focus on being a low-cost producer with advanced greenhouse operations.
Profitability: Fourth consecutive quarter of positive net income and 118% year-over-year growth in adjusted EBITDA.
Shift to higher-margin products: Strategic focus on higher-margin products in Canada, contributing to improved profitability.
M&A strategy: Adopting a cautious and disciplined approach to mergers and acquisitions, focusing on long-term shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Capacity Constraints: The company faced capacity constraints ahead of its expansion projects, which could limit revenue growth until these projects come online in the second half of the year.
Price Compression: Price compression is being observed in many parts of the supply chain, which could impact profitability in certain markets.
Regulatory Delays: The company experienced delays in receiving final certification and regulatory approval for its Phase 2 facility in the Netherlands, which could impact the timing of sales contributions.
Tax Payments Impacting Cash Flow: Large Canadian corporate income tax payments in Q1 resulted in negative cash flow from operations, though the company expects to return to positive cash flow in subsequent quarters.
Seasonality in Dutch Market: Seasonal consumer behavior in the Netherlands led to a minor sequential sales decline, which could affect revenue predictability in this region.
Uncertainty in U.S. Cannabis Regulation: While rescheduling of cannabis in the U.S. is seen as a positive development, significant regulatory uncertainty remains, particularly in Texas, which could impact the company's U.S. strategy.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects increased sales during the second half of 2026, driven by expansion projects coming online. International export sales are anticipated to grow, with multiple new jurisdictions expected to be entered during the year.
Production Capacity: Facility upgrades in British Columbia have significantly expanded production capacity for EU GMP-compliant cannabis. The Delta 2 expansion is expected to add 40 metric tons of annual capacity by mid-2027, with an incremental 15 metric tons expected in 2026.
Market Trends: The German market is expected to remain stable with increasing demand for EU GMP-compliant products. Pricing in Germany is anticipated to remain stable due to stricter regulations and enforcement in international markets.
Netherlands Operations: The Groningen facility is expected to commence full operations by the end of Q2 2026, contributing to stronger sales and adjusted EBITDA performance in the second half of the year.
U.S. Market Strategy: The company is evaluating opportunities in the U.S. market following regulatory changes, with potential for medical cannabis exports and partnerships. However, the company plans to remain patient and selective in pursuing opportunities.
Profitability Outlook: The company expects to continue profitable growth through 2027, supported by expanded capacity, stable pricing, and increased demand in key markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company has been active with its share repurchase program. The Board approved up to a $10 million buyback, allowing the purchase of up to 5% of shares in a 12-month period. During Q1, over 2 million shares were repurchased at an aggregate cost of $6.4 million. The program was completed in its entirety during the second quarter. The Board and management will continue to evaluate capital allocation decisions quarterly, maintaining a balanced approach to drive shareholder returns.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide details on the confidence in price stability for 2026 and the margin difference between Canada and international exports?
A:The CEO stated they would not provide details on the margin difference as it is kept internal. Regarding price compression, the company has not seen margin compression for their EU GMP certified product, attributing this to the product's quality and compliance. They noted that price compression is affecting others due to non-compliant products.
Q:How aggressive might the company get in M&A given potential U.S. exports and regulatory uncertainties?
A:The CEO emphasized a prudent approach, avoiding capital deployment without regulatory clarity. They cited past mistakes, such as the CBD business acquisition, as a reason for caution. They expect clarity in 3-6 months and highlighted discrepancies in valuations between public and private companies as another factor for caution.
Q:How is the company capturing market share and maintaining stable pricing in Germany?
A:The CEO attributed success to their focus on EU GMP compliance from the start, avoiding shortcuts. They emphasized their investment in supply chain, quality, and consistency over multiple years. The COO added that their supply chain investments have led to scale, consistency, and price stability.
Q:What are the supply-demand dynamics and pricing trends in the Netherlands?
A:The COO noted that supply has improved as competitors are fully operational, leading to some pricing softness, which was anticipated. The CEO added that the market is finite, with 590 coffee shops and 80 participating in the pilot program. They modeled market compression over four years and highlighted consumer behavior, such as daily purchases of small quantities.
Q:Could there be changes to the Netherlands pilot program after the summer review?
A:The CEO expressed optimism, citing positive feedback from regulators and minimal infractions. They believe the review will be favorable. The COO clarified that the company sells throughout the Netherlands and noted an expansion into form factors due to a sophisticated consumer base.
Q:Can MSOs be cost-competitive if allowed to export to Germany?
A:The CEO refrained from making assumptions but noted the challenges of scaling up and regulatory hurdles, such as DEA approval for each shipment. The COO emphasized their leadership in cost of production and ongoing efforts to reduce costs further.
Q:Review of Unclear Management Responses
A:The CEO avoided providing details on the margin difference between Canada and international exports, stating it is kept internal.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Delta expansion
Drachten facility
EU GMP
GMP cannabis
Netherlands delay
Phase facility
Village Farms
approval
brand
building
cannabis market
cannabis segment
cannabis world
capacity constraint
category
change
consumer
contribution sale
cost production
expectation capacity
facility Netherlands
facility sale
flow remainder
income tax
line expectation
order
partner
plant
price
reminder
reporting
repurchase
sale channel
share position
shift margin
speculation
supply chain
unit
week
VFF Transcript
Village Farms International, Inc. (VFF) Q1 2026 Earnings Call Transcript
Positive5-11
The earnings call summary shows strong financial performance with a 27% increase in net sales and a 118% rise in EBITDA. The share repurchase program and increased gross margins are positive indicators. Although cash flow was negative, it is expected to improve. The Q&A section highlighted management's prudent approach to M&A and confidence in market strategy, despite some reluctance to disclose margin details. Overall, the company's performance and strategic decisions suggest a positive outlook for the stock price.
Village Farms International, Inc. (VFF) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call highlights strong financial performance, including a significant increase in global cannabis sales, net income, and adjusted EBITDA. The share repurchase program indicates confidence in the company's valuation. While there were concerns about the German market, management expects growth to rebound. The strategic expansion and operational efficiencies in Canada and internationally are promising. The lack of specific guidance on cost initiatives is a minor concern, but overall, the positive financial metrics and strategic plans suggest a positive stock price movement.
Village Farms International, Inc. (VFF) Q3 2025 Earnings Call Transcript
Positive11-10
The earnings call highlights strong financial performance, with record net sales, net income, and EBITDA. Growth in Canadian and Netherlands cannabis markets is robust, with significant international expansion plans. Despite some uncertainties in the Q&A, the optimistic guidance, especially in international markets, aligns with a positive outlook. The company's strong financial metrics, optimistic guidance, and strategic market expansion drive a strong positive sentiment, likely resulting in a stock price increase over the next two weeks.
Village Farms International, Inc. (VFF) Q2 2025 Earnings Call Transcript
Positive8-11
The earnings call highlights strong international growth, improved margins, and a solid net cash position. Despite a decline in Canadian retail sales, the focus on high-margin products and international expansion is promising. The Q&A reveals management's strategic focus on growth and profitability, with potential upside from U.S. regulatory changes. Positive factors outweigh concerns, suggesting a positive stock price movement.
VFF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
